Relation Between Bone Mineral Density, Gross Motor Function and Quality of Life In Children With Cerebral Palsy

March 5, 2024 updated by: Shimaa Talaat Elsayed Emara, Cairo University

studying the relationship between Bone Mineral Density, Gross Motor Function and, Quality of Life with CP can provide valuable insights into the musculoskeletal consequences of motor impairments and guide interventions to improve bone health.

Statement of the problem Is there a relation between Bone Mineral Density, Gross Motor Function and Quality of Life in children with CP ? Purpose of the study

To study the relationship between:

  1. Bone Mineral Density and Gross Motor Function in ambulant and non-ambulant CP children.
  2. Bone Mineral Density and Quality of Life in ambulant and non-ambulant CP children.
  3. Gross Motor Function and Quality of Life in ambulant and non-ambulant CP children.

Study Overview

Detailed Description

Cerebral palsy (CP) is primarily a neuromotor disorder that affects the development of movement, muscle tone and posture. The underlying pathophysiology is an injury to the developing brain in the prenatal through neonatal period. Although the initial neuro pathologic lesion is non-progressive, children with cerebral palsy may develop a range of secondary conditions over time that will variably affect their functional abilities. The prevalence of CP varies between 1.5 to more than 4 cases per 1,000 live births worldwide. The motor impairments associated with CP can range from mild to severe, affecting different muscle groups and leading to difficulties in activities of daily living and participation in social and recreational activities.

Children with CP often experience motor impairments that affect their gross motor function, leading to limitations in activities and participation. These motor impairments can also have a negative impact on bone health, resulting in reduced bone mineral density (BMD) and increased risk of skeletal complications.

Gross motor function (GMF) refers to the ability to perform coordinated movements using large muscle groups, such as walking, running, and jumping. It is a key aspect of physical ability and independence in daily activities for children with CP. Previous research has shown that gross motor function is closely associated with bone health in this population. However, further investigation is needed to explore the specific nature of this correlation and its implications for intervention strategies.

Gross motor function is commonly assessed using standardized tools such as the Gross Motor Function Classification System (GMFCS) or the Gross Motor Function Measure (GMFM). Quality of life is a multidimensional construct that encompasses physical, psychological, and social well-being. In the context of cerebral palsy, understanding the impact of gross motor function on quality of life is crucial for comprehensive care and intervention planning. Children with CP may face limitations in mobility, participation in activities, and social interactions, which can significantly affect their overall quality of life. Exploring the relationship between gross motor function and quality of life can provide valuable insights into the factors influencing the holistic well-being of children with CP.

The quality of life in children with CP is not only influenced by their motor function but also by their overall health and well-being. Bone health plays a crucial role in maintaining the physical abilities and independence of individuals, as well as their overall quality of life. Impaired bone health in children with CP can lead to limitations in mobility, increased pain, and reduced participation in activities, which can have a significant impact on their overall well-being.

Bone mineral density, on the other hand, is an important measure of bone strength and overall skeletal health. Children with CP often exhibit lower BMD compared to typically developing peers due to factors such as reduced weight-bearing activities, muscle weakness, altered biomechanics, limited mobility, and hormonal imbalances. This reduced BMD increases their susceptibility to fractures and skeletal deformities, further impacting their functional abilities and quality of life.

Study Type

Observational

Enrollment (Estimated)

75

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Giza, Egypt
        • Recruiting
        • faculty of medicine , Cairo University
        • Contact:
          • shimaa Emara, M.Sc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Seventy- five CP Children will be divided into two groups according to GMFCS:

  1. Group 1 (Ambulant ) consisted of 35 children with CP classified to level I, II and III according to GMFCS.
  2. Group 2 (Non-Ambulant ) consisted of 35 children with CP classified to level IV and V according to GMFCS.

All measured variables will be identified for children of both groups, then correlation between BMD, gross motor function and QoL will be determined.

Description

Inclusion Criteria:

  1. Children with CP (spastic diplegia and quadriplegia).
  2. Their chronological ages will be ranged from 7 to 10 years.
  3. They will be selected from both genders.
  4. Their motor function will be at any Level according to GMFCS.
  5. Their body mass index (BMI ) will be normal.

Exclusion criteria

Children will be excluded from the study if they have any of the following :

  1. Underweight, Overweight or Obese.
  2. Epilepsy , kidney problems that make them taking hormonal treatments or drugs affect bone density or taking calcium, vitamin D, steroids during 6 months prior to the study.
  3. Fracture in the measurement areas.
  4. Hip Flexion deformity more than 30° when posed to measure.
  5. Internal metallic fixations in the measurement areas (neck of femur and lumber vertebra from L1-L4).
  6. Hyperthyroidism or Hypothyroidism.
  7. Hypotonia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1 (Ambulant )

consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:

  1. Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).
  2. Gross motor function measurement scale (GMFM) will be used to assess gross motor function.
  3. Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL).

consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:

Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).

Gross motor function measurement scale (GMFM) will be used to assess gross motor function.

Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL).

Other Names:
  • Ambulant
Group 2 (Non-Ambulant )

consisted of 38 children with CP classified to level IV and V according to GMFCS.then:

  1. Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).
  2. Gross motor function measurement scale (GMFM) will be used to assess gross motor function.
  3. Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL).

consisted of 38 children with CP classified to level IV and V according to GMFCS. then:

Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).

Gross motor function measurement scale (GMFM) will be used to assess gross motor function.

Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL).

Other Names:
  • Non-Ambulant

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dual-energy X-ray absorptiometry (DXA) scans
Time Frame: 1 day
Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).
1 day
Gross motor function measurement scale (GMFM)
Time Frame: 1 day
Gross motor function measurement scale (GMFM) will be used to assess gross motor function.
1 day
Quality of Life Questionnaire for Children (CP QOL-Child)
Time Frame: 1 day
Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL).
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Elham Elsayed Salem, professor, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2024

Primary Completion (Estimated)

March 1, 2024

Study Completion (Estimated)

April 1, 2024

Study Registration Dates

First Submitted

December 5, 2023

First Submitted That Met QC Criteria

December 21, 2023

First Posted (Actual)

December 22, 2023

Study Record Updates

Last Update Posted (Estimated)

March 6, 2024

Last Update Submitted That Met QC Criteria

March 5, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Palsy

Clinical Trials on Group 1

Subscribe